CStone Pharmaceuticals
| Public | |
| Traded as | |
| ISIN | 🆔 |
| Industry | |
| Founded 📆 | 2015 in Shanghai |
| Founder 👔 | |
| Headquarters 🏙️ | 21st Floor No. 399 West Haiyang Road, Shanghai , China |
Area served 🗺️ | |
Key people | Dr. Ningjun Jiang M.D., Ph.D. |
| Products 📟 | Pharmaceuticals |
| Members | |
Number of employees | |
| 🌐 Website | en |
| 📇 Address | |
| 📞 telephone | |
CStone Pharmaceuticals is a Chinese pharmaceutical company that focuses on the development and commercialization of immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment worldwide.
The company's notable projects include pralsetinib, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers[1]; avapritinib, an KIT/PDGFRA inhibitor for the treatment of for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation[2]; ivosidenib, an IDH1 inhibitor to treat patients with IDH1 mutant relapsed or refractory acute myeloid leukemia[3], and fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma[4]
In September 2020, Pfizer acquired a 9.9% stake in the company for $200 million (HK$1.55 billion), helping to commercialise its anti-PD-L1 monoclonal antibody, CS1001.[5]
See also[edit]
References[edit]
- ↑ GmbH, finanzen net. "CStone Announces New Drug Approval of GAVRETO(R) (pralsetinib) as First Selective RET Inhibitor in China, Providing a New Therapy for a Subset of Non-Small Cell Lung Cancer Patients". markets.businessinsider.com.
- ↑ "CStone announces enrollment target reached in the global Phase III VOYAGER trial of avapritinib in Chinese patients with third-line GIST". December 11, 2019.
- ↑ https://investor.agios.com/news-releases/news-release-details/agios-and-cstone-pharmaceuticals-announce-exclusive
- ↑ "Blueprint, CStone Enroll First Patient in Phase Ib/II Trial for FGFR4-Driven Liver Cancer". Precision Oncology News. January 6, 2020.
- ↑ "Pfizer to buy 9.9% of CStone for $200 million, eyes collaboration". September 30, 2020 – via www.reuters.com.
 | This Chinese corporation or company article is a stub. You can help EverybodyWiki by expanding it. |
 | This China-related article is a stub. You can help EverybodyWiki by expanding it. |
This article "CStone Pharmaceuticals" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:CStone Pharmaceuticals. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
